Comment from Goldwater Institute

Summary: The Goldwater Institute, a nonpartisan public policy and research foundation, supports the FDA's draft guidance on the plausible mechanism framework for individualized therapies. They advocate for accelerating patient access to these treatments while emphasizing the importance of physician oversight, IRB approval, and the potential for "deputizing" IRBs to reduce administrative bottlenecks.